The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1β and TNF-α
- Cite this article as:
- Magne, D., Mézin, F., Palmer, G. et al. Inflamm. res. (2006) 55: 469. doi:10.1007/s00011-006-5196-x
Objective and design
Excessive synovial fibroblast (SF) proliferation is detrimental in rheumatoid arthritis. We therefore sought to determine the effects of A77 1726, the active metabolite of leflunomide, on SF proliferation.
Human SFs were used. Cell proliferation was investigated using MTS assay, by 3H-thymidine incorporation and cell counts.
Whereas A77 1726 alone had no effects, it significantly increased the mitogenic effects of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α). Cyclooxygenase inhibition might be at least partly involved, since indomethacin displayed similar effects, and since prostaglandin E2 inhibited SF proliferation. In contrast, the effect of A77 1726 did not appear to be mediated through depletion of the pyrimidine pool or inhibition of tyrosine kinases.
A77 1726 displays proliferative effects in presence of IL-1β and TNF-α. Further elucidation of involved mechanisms may prove useful for the utilization of leflunomide, the development of related compounds or elaboration of new therapeutic strategies.
Key words.Leflunomide Rheumatoid arthritis Synovial fibroblast Proliferation Cyclooxygenase
disease-modifying anti-rheumatic drug
tumor necrosis factor-α.